期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

谷胱甘肽巯基转移酶对肿瘤化疗药物耐药的影响 被引量：1

原文传递
导出
摘要 肿瘤对化疗药物的内源性或获得性的耐药是目前肿瘤化疗失败的重要原因。耐药现象产生的原因有多种：多药耐药相关蛋白表达变化，药物代谢或摄取发生变化，药物靶标分子的突变、增殖或凋亡关键基因（如p53）的改变造成细胞逃避凋亡，药物解毒酶如谷胱甘肽巯基转移酶（glutathionine S—transferase，GST）的过表达等。本文就GST对肿瘤化疗耐药性的影响的相关研究作一综述。
作者 钱学珂 廖宁
机构地区 广东省医学科学院广东省人民医院肿瘤中心乳腺科
出处 《中华乳腺病杂志（电子版）》 CAS 2013年第3期55-60,共6页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 谷胱甘肽巯基转移酶 肿瘤抗药性
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献70

  • 1Mcllwain CC, Townsend DM,Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy [ J].Oncogene, 2006, 25(11) : 1639-1648.
  • 2Sau A, Pellizzari Tregno F, Valentino F, et ai. Glutathionetransferases and development of new principles to overcome drugresistance[J]. Arch Biochem Biophys, 2010 , 500(2) : 116-122.
  • 3Arai T, Miyoshi Y, Kim SJ, et al. Association of GST PIexpression with resistance to docetaxel and paclitaxel in humanbreast cancers[ J]. Eur J Surg Oncol, 2008 , 34(7) :734-738.
  • 4Tew KD. Glutathione-associated enzymes in anticancer drugresistance[ J]. Cancer Res, 1994,54(16): 4313-4320.
  • 5Hayes JD, McLellan LI. Glutathione and glutathione-dependentenzymes represent a coordinately regulated defence againstoxidative stress[ J]. Free Radic Res, 1999,31(4) : 273-300.
  • 6Hayes JD, Strange RC. Glutathione S-transferase polymorphismsand their biological consequences [ J]. Pharmacology,2000,61(3): 154-166.
  • 7Pemble SE, Wardle AF, Taylor JB. Glutathione S-transferaseclass Kappa : characterization by the cloning of rat mitochondrialGST and identification of a human homologue[ J]. Biochem J,1996,319 (Pt 3) : 749-754.
  • 8Jakobsson PJ, Morgensterm R, Mancini J, et al. Commonstructural features of MAPEG — a widespread superfamily ofmembrane associated proteins with highly divergent functions ineicosanoid and glutathione metabolism [ J]. Protein Sci, 1999,8(3): 689-692.
  • 9Strange RC, Spiteri MA, Ramachandran S,et al. Glutathione-S-transferase family of enzymes[ J]. Mutat Res, 2001,482( 1/2) : 21-26.
  • 10Ji X, Blaszczyk J, Xiao B, et al. Structure and function ofresidue 104 and water molecules in the xenobiotic substrate-binding site in human glutathione S-transferase Pl-1 [ J].Biochemistry, 1999,38(32) : 10 231-10 238.

同被引文献13

  • 1陆建伟,高长明,吴建中,孙小峰,王丽,冯继锋.亚甲基四氢叶酸还原酶基因C677T多态性与胃癌患者对5-FU化疗敏感性的关系[J].癌症,2004,23(8):958-962. 被引量：20
  • 2袁芃,缪小平,张雪梅,王中华,谭文,张湘茹,孙燕,徐兵河,林东昕.核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系[J].癌症,2005,24(12):1510-1513. 被引量：46
  • 3Snozek CL, O'Kane D J, Algeciras-Schimnieh A. Pharmacogenelics of solid tumors : directed therapy in breast,lung, and colorectal cancer: a paper from the 2008 william beanmont hospital symposium on molec- ular pathology[ J]. J Mol Diagn,2009,11 ( 5 ) :381 - 389.
  • 4Zhu LB,Xu Q, Hong CY, et al. XPC gene intron 11 C/A polymor- phism is a predictive biomarker for the sensitivity to NP chemothera- py in patients with non-small cell lung cancer[ J ]. Anticancer Drugs, 2010,21 (7) :669 -673.
  • 5Health Quality Ontario Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyro- sine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non- Small-Cell Lung Cancer: An Evidence-Based Analysis [ J ]. Ont Health Technol Assess Ser,2010,10(24) :1 -48.
  • 6Kimura T, Okamoto K, Miyamoto H, et al. Clinical benefit of high- sensitivity KRAS mutation testing in metastatic colorectal cancer trea- ted with anti-EGFR antibody therapy [ J ]. Oncology, 2012,82 ( 5 ) : 298 - 304.
  • 7Cizkova M, Dujaric ME, Lehmann-Che J, et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab[ J]. Br J Cancer,2013,108(9) :1807 - 1809.
  • 8Eghelakin A, Ferguson M J, MacGill EA, et al. Increased risk of vin- cristine neurotoxicity associated with low CYP3 A5 expression geno- type in children with acute lymphoblastic leukemia [ J ]. Pediatr Blood Cancer,2011,56(3 ) :361 - 367.
  • 9Ichikawa W. Prediction of clinical outcome of fluoropyrimidine-basedchemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway [ J ]. Gastric Cancer,2006,9 ( 3 ) : 145 - 155.
  • 10Terashima M,lrinoda T, Fujiwara H, et al. Roles of thymidylate syn- thase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluomuracil in human gastric cancer [ J ]. Anticancer Res,2002,22 ( 2A ) : 761 - 768.

引证文献1

中华乳腺病杂志（电子版）
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部